RT Journal Article SR Electronic T1 No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1713 OP 1716 DO 10.2967/jnumed.119.229062 VO 60 IS 12 A1 Helle D. Zacho A1 Mads R. Jochumsen A1 Niels C. Langkilde A1 Jesper C. Mortensen A1 Christian Haarmark A1 Helle W. Hendel A1 Jørgen B. Jensen A1 Lars J. Petersen YR 2019 UL http://jnm.snmjournals.org/content/60/12/1713.abstract AB The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.